Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Bhagirath V, Liaw PC, Weitz JI, Julian JA
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018 05 10; 131(19):2151-2160.
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.
Daniel V, Huber W, Bauer K, Suesal C, Mytilineos J, Melk A, Conradt C, Opelz G
Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies. Arch Environ Health. 2001 Jan-Feb; 56(1):77-83.
Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies.
Turpie AG, Bauer KA, Eriksson BI, Lassen MR
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002 Sep 09; 162(16):1833-40.
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG, Eriksson BI, Lassen MR, Bauer KA
Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol. 2003 Sep; 10(5):327-32.
Fondaparinux, the first selective factor Xa inhibitor.
Conway EM, Bauer KA, Barzegar S, Rosenberg RD
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest. 1987 Dec; 80(6):1535-44.
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
Váradi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE, Keil B, Schwarz HP
A chromogenic assay for activated protein C resistance. Br J Haematol. 1995 Aug; 90(4):884-91.
A chromogenic assay for activated protein C resistance.
van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA
Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996 Mar; 75(3):417-21.
Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.
Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. Thromb Res. 1999 Mar 15; 93(6):265-9.
Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms.
Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H
Arteriosclerosis, thrombosis, and vascular biology
Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000 Nov; 20(11):2489-93.
Activation of clotting factors XI and IX in patients with acute myocardial infarction.
Journal of thrombosis and haemostasis : JTH
Targeted inhibition of coagulation: oral agents show promise in phase III trials. J Thromb Haemost. 2007 Nov; 5(11):2175-7.
Targeted inhibition of coagulation: oral agents show promise in phase III trials.
Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, Catanese J, Reitsma PH, Doggen CJ, Devlin JJ, Rosendaal FR, Bare LA
F9 Malmö, factor IX and deep vein thrombosis. Haematologica. 2009 May; 94(5):693-9.
F9 Malmö, factor IX and deep vein thrombosis.
Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991 Jan; 28(1):10-8.
Role of antithrombin III as a regulator of in vivo coagulation.
Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system". J Med. 1985; 16(1-3):351-416.
Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system".
Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost. 2002 Jun; 28 Suppl 2:15-24.
Selective inhibition of coagulation factors: advances in antithrombotic therapy.
Turpie AG, Eriksson BI, Bauer KA, Lassen MR
New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest. 2003 Dec; 124(6 Suppl):371S-378S.
New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM, Rosenberg RD
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 1988 May; 71(5):1418-26.
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency.
Lee AY, Gent M, Julian JA, Bauer KA, Eriksson BI, Lassen MR, Turpie AG
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. J Thromb Haemost. 2004 Oct; 2(10):1752-9.
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review.
Pollak ES, Russell TT, Ptashkin B, Smith-Whitley K, Camire RM, Bauer KA
Asymptomatic factor VII deficiency in African Americans. Am J Clin Pathol. 2006 Jul; 126(1):128-32.
Asymptomatic factor VII deficiency in African Americans.
Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, Ford C, Pressel S, Walldius G, Jungner I, Folsom AR, Chambless LE, Knuiman M, Whincup PH, Wannamethee SG, Morris RW, Willeit J, Kiechl S, Santer P, Mayr A, Wald N, Ebrahim S, Lawlor DA, Yarnell JW, Gallacher J, Casiglia E, Tikhonoff V, Nietert PJ, Sutherland SE, Bachman DL, Keil JE, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, Giampaoli S, Palmieri L, Panico S, Vanuzzo D, Pilotto L, Simons L, McCallum J, Friedlander Y, Fowkes FG, Lee AJ, Smith FB, Taylor J, Guralnik J, Phillips C, Wallace R, Blazer D, Khaw KT, Jansson JH, Donfrancesco C, Salomaa V, Harald K, Jousilahti P, Vartiainen E, Woodward M, D'Agostino RB, Wolf PA, Vasan RS, Pencina MJ, Bladbjerg EM, Jorgensen T, Moller L, Jespersen J, Dankner R, Chetrit A, Lubin F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Bjorkelund C, Cremer P, Nagel D, Tilvis R, Strandberg T, Rodriguez B, Bouter LM, Heine RJ, Dekker JM, Nijpels G, Stehouwer CD, Rimm E, Pai J, Sato S, Iso H, Kitamura A, Noda H, Goldbourt U, Salomaa V, Salonen JT, Nyyssönen K, Tuomainen TP, Deeg D, Poppelaars JL, Meade T, Cooper J, Hedblad B, Berglund G, Engstrom G, Döring A, Koenig W, Meisinger C, Mraz W, Kuller L, Selmer R, Tverdal A, Nystad W, Gillum R, Mussolino M, Hankinson S, Manson J, De Stavola B, Knottenbelt C, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Naito Y, Holme I, Nakagawa H, Miura H, Ducimetiere P, Jouven X, Crespo C, Garcia-Palmieri M, Amouyel P, Arveiler D, Evans A, Ferrieres J, Schulte H, Assmann G, Shepherd J, Packard C, Sattar N, Cantin B, Lamarche B, Després JP, Dagenais GR, Barrett-Connor E, Wingard D, Bettencourt R, Gudnason V, Aspelund T, Sigurdsson G, Thorsson B, Trevisan M, Witteman J, Kardys I, Breteler M, Hofman A, Tunstall-Pedoe H, Tavendale R, Lowe GD, Ben-Shlomo Y, Howard BV, Zhang Y, Best L, Umans J, Onat A, Meade TW, Njolstad I, Mathiesen E, Lochen ML, Wilsgaard T, Gaziano JM, Stampfer M, Ridker P, Ulmer H, Diem G, Concin H, Rodeghiero F, Tosetto A, Brunner E, Shipley M, Buring J, Cobbe SM, Ford I, Robertson M, He Y, Ibanez AM, Feskens EJ, Kromhout D, Collins R, Di Angelantonio E, Kaptoge S, Lewington S, Orfei L, Pennells L, Perry P, Ray K, Sarwar N, Scherman M, Thompson A, Watson S, Wensley F, White IR, Wood AM
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007; 22(12):839-69.
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.
Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ
Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost. 1992 May 04; 67(5):503-6.
Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease.
New insights into hypercoagulable states. Hosp Pract (Off Ed). 1986 Mar 15; 21(3):131-8, 143, 147.
New insights into hypercoagulable states.
Weinstein MJ, Chute LE, Schmitt GW, Hamburger RH, Bauer KA, Troll JH, Janson P, Deykin D
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest. 1985 Oct; 76(4):1406-11.
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.
Cohen LJ, McWilliams NB, Neuberg R, Zinkham W, Bauer K, Gribble TJ, Glowalla MB, Borson R, Phillips MD, Kunschak M
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. Am J Hematol. 1995 Dec; 50(4):269-76.
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.
Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD
Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995 Jun 01; 85(11):3144-9.
Hypercoagulability in centenarians: the paradox of successful aging.
Greengard JS, Eichinger S, Griffin JH, Bauer KA
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med. 1994 Dec 08; 331(23):1559-62.
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.
Conard J, Bauer KA, Gruber A, Griffin JH, Schwarz HP, Horellou MH, Samama MM, Rosenberg RD
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15; 82(4):1159-64.
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency.
Kistler JP, Singer DE, Millenson MM, Bauer KA, Gress DR, Barzegar S, Hughes RA, Sheehan MA, Maraventano SW, Oertel LB
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. Stroke. 1993 Sep; 24(9):1360-5.
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators.
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. Lancet. 2003 Nov 08; 362(9395):1582-3.
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery.
New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest. 2003 Dec; 124(6 Suppl):364S-370S.
New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler JP
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology. 2004 Sep 14; 63(5):777-84.
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Lee MH, Kaczmarek E, Chin DT, Oda A, McIntosh S, Bauer KA, Clyne LP, McDonagh J
Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization. Blood. 1991 Oct 01; 78(7):1744-52.
Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005 Nov; 3(11):2479-86.
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
New anticoagulants: anti IIa vs anti Xa--is one better? J Thromb Thrombolysis. 2006 Feb; 21(1):67-72.
New anticoagulants: anti IIa vs anti Xa--is one better?
Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost. 2008 02; 6(2):259-67.
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII).
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):141S-159S.
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B
Clinical cancer research : an official journal of the American Association for Cancer Research
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40.
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.
Hypercoagulability--a new cofactor in the protein C anticoagulant pathway. N Engl J Med. 1994 Feb 24; 330(8):566-7.
Hypercoagulability--a new cofactor in the protein C anticoagulant pathway.
Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 05 16; 373(9676):1673-80.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. Hum Pathol. 1987 Mar; 18(3):253-62.
Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S.
Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD
Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood. 1983 Dec; 62(6):1242-50.
Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia.
Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood. 1994 Aug 15; 84(4):1314-9.
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients.
ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, Buller HR, Hack CE, ten Cate JW, Rosenberg RD
Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost. 1996 Mar; 75(3):445-9.
Factor XIa induced activation of the intrinsic cascade in vivo.
New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010; 7(1):1-8.
New oral anticoagulants in development: potential for improved safety profiles.
Lopaciuk S, Windyga J, Watala CW, Bykowska K, Pietrucha T, Kwiecinski H, Czlonkowska A, Kuczynska-Zardzewialy A, Jackson AA, Carew JA, Bauer KA
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Polymorphisms in the factor VII gene and ischemic stroke in young adults. Blood Coagul Fibrinolysis. 2010 Jul; 21(5):442-7.
Polymorphisms in the factor VII gene and ischemic stroke in young adults.
Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR, Bauer K, Rosenberg RD
Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res. 1989 Jun 15; 54(6):613-9.
Antithrombin Chicago, amino acid substitution of arginine 393 to histidine.
Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD
Journal of the American College of Cardiology
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995 Jan; 25(1):203-9.
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.
Schmaier AH, Dahl LD, Hasan AA, Cines DB, Bauer KA, Van Nostrand WE
Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. Biochemistry. 1995 Jan 31; 34(4):1171-8.
Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes.
Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD
Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996 May; 75(5):767-71.
Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease.
Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG
Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost. 2004 Feb; 2(2):242-7.
Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family.
Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, Shrivastava S, Ridker PM
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Oct; 4(10):2199-203.
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial.
Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 1990 Dec 15; 76(12):2540-5.
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Arbini AA, Bodkin D, Lopaciuk S, Bauer KA
Molecular analysis of Polish patients with factor VII deficiency. Blood. 1994 Oct 01; 84(7):2214-20.
Molecular analysis of Polish patients with factor VII deficiency.
Chowdhury V, Olds RJ, Lane DA, Conard J, Pabinger I, Ryan K, Bauer KA, Bhavnani M, Abildgaard U, Finazzi G
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol. 1993 Aug; 84(4):656-61.
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening.
Merlini PA, Ardissino D, Bauer KA, Oltrona L, Pezzano A, Bottasso B, Rosenberg RD, Mannucci PM
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1997 Jul; 17(7):1325-30.
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Teitel JM, Bauer KA, Lau HK, Rosenberg RD
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood. 1982 May; 59(5):1086-97.
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.
Archives of pathology & laboratory medicine
Laboratory markers of coagulation activation. Arch Pathol Lab Med. 1993 Jan; 117(1):71-7.
Laboratory markers of coagulation activation.
Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun; 129(6):753-6.
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate.
A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. Blood. 1996 Jun 15; 87(12):5085-94.
A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule.
The role of the laboratory in preventing and diagnosing arterial or veinal thrombotic accidents, and in monitoring their treatment. Ann Biol Clin (Paris). 1985; 43(4):451-4.
The role of the laboratory in preventing and diagnosing arterial or veinal thrombotic accidents, and in monitoring their treatment.
Bovill EG, Bauer KA, Dickerman JD, Callas P, West B
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989 Feb 15; 73(3):712-7.
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred.
Bauer KA, Goodman TL, Kass BL, Rosenberg RD
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest. 1985 Aug; 76(2):826-36.
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.
Eichinger S, Mannucci PM, Tradati F, Arbini AA, Rosenberg RD, Bauer KA
Determinants of plasma factor VIIa levels in humans. Blood. 1995 Oct 15; 86(8):3021-5.
Determinants of plasma factor VIIa levels in humans.
Merlini PA, Ardissino D, Bauer KA, Oltrona L, Spinola A, Diotallevi P, Rosenberg RD, Mannucci PM
Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood. 1995 Nov 01; 86(9):3327-32.
Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris.
Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994 Jan; 93(1):114-20.
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.
Prothrombin activation fragment assay. Clin Chem. 1993 Apr; 39(4):559-60.
Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Büller HR
Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001 May 29; 103(21):2555-9.
Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.
Gilchrist A, Solomon N, Erickson D, Sikand A, Bauer KA, Kruskall MS, Kocher O
Clinica chimica acta; international journal of clinical chemistry
Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. Clin Chim Acta. 2001 Dec; 314(1-2):249-54.
Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay.
American journal of orthopedics (Belle Mead, N.J.)
Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Am J Orthop (Belle Mead NJ). 2002 Nov; 31(11 Suppl):4-10.
Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA, Dentali F, Lansing J, Balduzzi S, Darzi A, Morgano GP, Neumann I, Nieuwlaat R, Yepes-Nuñez JJ, Zhang Y, Wiercioch W
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 11 27; 2(22):3198-3225.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res. 1983 Feb 15; 29(4):437-42.
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state.
Hematology. American Society of Hematology. Education Program
New anticoagulants. Hematology Am Soc Hematol Educ Program. 2006; 450-6.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
Successful treatment of ligneous gingivitis with warfarin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan; 107(1):77-80.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Successful treatment of ligneous gingivitis with warfarin.
Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med. 1989 Sep 11; 87(3B):53S-60S.
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
Conway EM, Lau HK, Bauer KA, Rosenberg RD
The Journal of laboratory and clinical medicine
Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma. J Lab Clin Med. 1987 Nov; 110(5):567-75.
Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma.
Thrombin generation in acute promyelocytic leukemia. Blood. 1984 Oct; 64(4):791-6.
Thrombin generation in acute promyelocytic leukemia.
Hunault M, Marsh-Scott C, Jou C, Marshall R, Scheffel C, Fiore LD, Bauer KA, Mitchell MJ
Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay. Clin Chem. 1999 Jan; 45(1):41-6.
Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay.
Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: don't bother. Thromb Haemost. 2001 Mar; 85(3):377-8.
Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: don't bother.
Best practice & research. Clinical haematology
Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Pract Res Clin Haematol. 2004 Mar; 17(1):89-104.
Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
Low intensity warfarin: is it clinically useful in venous thromboembolism management? Br J Haematol. 2004 Oct; 127(2):155-8.
Low intensity warfarin: is it clinically useful in venous thromboembolism management?
Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005 Dec; 183(2):283-92.
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.
Kocher O, Cirovic C, Malynn E, Rowland CM, Bare LA, Young BA, Henslee JG, Laffler TG, Huff JB, Kruskall MS, Wong G, Bauer KA
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. Am J Clin Pathol. 2007 Jan; 127(1):68-75.
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients.
Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 02 21; 4(4).
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.
Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, Chambless L, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Thompson SG, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Levy D, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen J, Nyyssönen K, Tuomainen TP, Hedblad B, Engström G, Berglund G, Loewel H, Koenig W, Hense HW, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Iso H, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Lowe GD, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Meade TW, Rudnicka A, Brennan P, Knottenbelt C, Cooper JA, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Lowe GD, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Di Angelantonio E, Kaptoge S, Lewington S, Lowe GD, Sarwar N, Thompson SG, Walker M, Watson S, White IR, Wood AM, Danesh J
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med. 2009 Apr 15; 28(8):1218-37.
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies.
Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP
Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med. 1983 Apr; 74(4):557-63.
Pulmonary complications associated with combination chemotherapy programs containing bleomycin.
ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993 Sep; 92(3):1207-12.
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 02 21; 380(8):720-728.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Kearon C, Parpia S, Spencer FA, Schulman S, Stevens SM, Shah V, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Connors JM, Ginsberg JS, Spadafora L, Julian JA
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. J Thromb Haemost. 2019 07; 17(7):1144-1152.
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
Veterans Affairs Boston Healthcare System
William Bosworth Castle Professor of Medicine , Emeritus
Corresponding Member of the Faculty of Medicine
Eche IM, Elsamadisi P, Wex N, Wyers MC, Brat GA, Cunningham K, Bauer KA
Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban. Pharmacotherapy. 2019 08; 39(8):861-865.
Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.
Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. Blood. 2020 01 30; 135(5):344-350.
Managing thromboembolic risk in patients with hereditary and acquired thrombophilias.
How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis? JAMA. 2020 01 14; 323(2):121-122.
How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis?
Yang S, Bauer KA, Singleton JM, Papavassiliou E, Kramer DB
Should You Treat This Acutely Ill Medical Inpatient With Venous Thromboembolism Chemoprophylaxis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2020 04 07; 172(7):484-491.
Should You Treat This Acutely Ill Medical Inpatient With Venous Thromboembolism Chemoprophylaxis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Neumann I, Izcovich A, Zhang Y, Rada G, Kahn SR, Spencer F, Rezende S, Dentali F, Bauer K, Morgano GP, Yepes-Nuñez JJ, Nieuwlaat R, Wiercioch W, Lu L, Wu J, Cushman M, Schunemann H
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv. 2020 04 14; 4(7):1512-1517.
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.
Carroll BJ, Beyer SE, Mehegan T, Dicks A, Pribish A, Locke A, Godishala A, Soriano K, Kanduri J, Sack K, Raber I, Wiest C, Balachandran I, Marcus M, Chu L, Hayes MM, Weinstein JL, Bauer KA, Secemsky EA, Pinto DS
Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team. Am J Med. 2020 11; 133(11):1313-1321.e6.
Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team.
Zwicker JI, Roopkumar J, Puligandla M, Schlechter BL, Sharda AV, Peereboom D, Joyce R, Bockorny B, Neuberg D, Bauer KA, Khorana AA
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020 05 26; 4(10):2254-2260.
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial.
Roithmaier A, Arlettaz R, Bauer K, Bucher HU, Krieger M, Duc G, Versmold HT
Randomized controlled trial of Ringer solution versus serum for partial exchange transfusion in neonatal polycythaemia. Eur J Pediatr. 1995 Jan; 154(1):53-6.
Randomized controlled trial of Ringer solution versus serum for partial exchange transfusion in neonatal polycythaemia.
In Memoriam: Professor Robert Daniel Rosenberg, 1937-2020. J Thromb Haemost. 2020 Jul; 18(7):1802-1803.
In Memoriam: Professor Robert Daniel Rosenberg, 1937-2020.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW
Extrapulmonary manifestations of COVID-19. Nat Med. 2020 07; 26(7):1017-1032.
Extrapulmonary manifestations of COVID-19.
Patell R, Khan AM, Bogue T, Merrill M, Koshy A, Bindal P, Joyce R, Aird WC, Neuberg D, Bauer KA, Zwicker JI
Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol. 2020 Oct; 95(10):E295-E296.
Heparin induced thrombocytopenia antibodies in Covid-19.
Patell R, Bogue T, Bindal P, Koshy A, Merrill M, Aird WC, Bauer KA, Zwicker JI
Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020 09; 18(9):2349-2357.
Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19.
Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI
Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 09 10; 136(11):1342-1346.
Postdischarge thrombosis and hemorrhage in patients with COVID-19.
Darzi AJ, Repp AB, Spencer FA, Morsi RZ, Charide R, Etxeandia-Ikobaltzeta I, Bauer KA, Burnett AE, Cushman M, Dentali F, Kahn SR, Rezende SM, Zakai NA, Agarwal A, Karam SG, Lotfi T, Wiercioch W, Waziry R, Iorio A, Akl EA, Schünemann HJ
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Adv. 2020 10 13; 4(19):4929-4944.
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.
Thrombolytic therapy in acute venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):612-618.
Thrombolytic therapy in acute venous thromboembolism.
Al-Samkari H, Gupta S, Leaf RK, Wang W, Rosovsky RP, Brenner SK, Hayek SS, Berlin H, Kapoor R, Shaefi S, Melamed ML, Sutherland A, Radbel J, Green A, Garibaldi BT, Srivastava A, Leonberg-Yoo A, Shehata AM, Flythe JE, Rashidi A, Goyal N, Chan L, Mathews KS, Hedayati SS, Dy R, Toth-Manikowski SM, Zhang J, Mallappallil M, Redfern RE, Bansal AD, Short SAP, Vangel MG, Admon AJ, Semler MW, Bauer KA, Hernán MA, Leaf DE
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. Ann Intern Med. 2021 05; 174(5):622-632.
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19.
Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 2021 07; 157:147-155.
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W
Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood. 1994 Oct 15; 84(8):2422-30.
Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells.
Research and practice in thrombosis and haemostasis
Aspirin thromboprophylaxis in joint replacement surgery. Res Pract Thromb Haemost. 2022 Jan; 6(1):e12649.
Aspirin thromboprophylaxis in joint replacement surgery.
Liu J, Elsamadisi P, Philips E, Bauer KA, Eche IM
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. Am J Health Syst Pharm. 2022 08 05; 79(16):1323-1329.
Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what's new? Blood Adv. 2023 09 26; 7(18):5199-5201.
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what's new?
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. J Thromb Haemost. 2023 12; 21(12):3508-3510.
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
The dos, don'ts, and nuances of thrombophilia testing. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):593-599.
The dos, don'ts, and nuances of thrombophilia testing.
Ryu J, Rämö JT, Jurgens SJ, Niiranen T, Sanna-Cherchi S, Bauer KA, Haj A, Choi SH, Palotie A, Daly M, Ellinor PT, Bendapudi PK
Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood. 2024 06 06; 143(23):2425-2432.
Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank.
Roberts HR, Bauer KA, Mann KG, Hennekens CH, Meade TW, Willerson JT, Higgins M
Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities. Ann Epidemiol. 1992 Jul; 2(4):553-6.
Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities.
Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health. 2013; 5:233-41.
Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency.
Ken-Dror G, Drenos F, Humphries SE, Talmud PJ, Hingorani AD, Kivimäki M, Kumari M, Bauer KA, Morrissey JH, Ireland HA
Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost. 2010 Nov; 8(11):2394-403.
Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.
Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7.
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).
Vestnik Rossiiskoi akademii meditsinskikh nauk
[Treatment and prevention of thrombotic episodes with hereditary thrombophilia]. Vestn Ross Akad Med Nauk. 1997; (1):32-7.
[Treatment and prevention of thrombotic episodes with hereditary thrombophilia].
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011 Jul; 9 Suppl 1:12-9.
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
Reversal of antithrombotic agents. Am J Hematol. 2012 May; 87 Suppl 1:S119-26.
Duration of anticoagulation: applying the guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2010; 2010:210-5.
Duration of anticoagulation: applying the guidelines and beyond.
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013 Jun; 44(6 Suppl 1):S38-40.
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA, Gerson W, Wright C, Wang J, McNicol E, Lanier RK, Kramer W, Carr DB
Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. J Clin Anesth. 2010 Nov; 22(7):510-8.
Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers.
Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism. JAMA. 2011 Apr 06; 305(13):1336-45.
Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism.
Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2012 Apr; 10(4):698-702.
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH.
Splanchnic vein thrombosis: management for the thrombosis specialist. J Thromb Haemost. 2025 Feb; 23(2):404-416.
Splanchnic vein thrombosis: management for the thrombosis specialist.
Steinberg BA, Beckley PD, Deering TF, Clark CL, Amin AN, Bauer KA, Cryer B, Mansour M, Scheiman JM, Zenati MA, Newby LK, Peacock WF, Bhatt DL
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. Crit Pathw Cardiol. 2013 Sep; 12(3):107-15.
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care.
Lubitz SA, Bauer KA, Benjamin EJ, Besdine RW, Forman DE, Gurol ME, Reddy VY, Singer DE
Journal of the American Geriatrics Society
Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc. 2013 Oct; 61(10):1798-803.
Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar.
Chiang CH, Song J, Chang YC, Osataphan S, Lee YC, Chang KY, Chi KY, Chiang CH, Dua A, Lake L, Lauw MN, Bauer KA, Kazi DS, Patell R
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation. Blood Adv. 2025 May 27; 9(10):2410-2418.
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.
Chaudhry SA, Haj AK, Ryu J, Jurgens SJ, Rodriguez Espada A, Wang X, Choi SH, Sanna-Cherchi S, Grover SP, Bauer KA, Ellinor PT, Bendapudi PK
Population-Scale Studies of Protein S Abnormalities and Thrombosis. JAMA. 2025 04 22; 333(16):1423-1432.
Population-Scale Studies of Protein S Abnormalities and Thrombosis.
Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013; 2013:464-70.
Pros and cons of new oral anticoagulants.
Chiang CH, Chang YC, Yu CC, See XY, Wang TH, Xanthavanij N, Song J, Lo SW, Chiang CH, Lake L, Lauw MN, Bauer KA, Kazi DS, Patell R
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2025 Nov; 23(11):3527-3539.
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.
Thomas CA, Theobald W, Knauer JP, Stoeckl C, Rosenberg MJ, Regan SP, Collins TJB, Goncharov VN, Betti R, Froula D, Deeney C, Anderson KS, Bauer KA, Bonino MJ, Cao D, Craxton RS, Edgell DH, Epstein R, Fess S, Forrest CJ, Glebov VY, Gopalaswamy V, Harding DR, Igumenshchev IV, Ivancic ST, Jacobs-Perkins DW, Janezic RT, Joshi T, Koch M, Kwiatkowski J, Lees A, Marshall FJ, Michalko M, Morse SFB, Patel D, Peebles JL, Radha PB, Rinderknecht HG, Sampat S, Sangster TC, Shah RC, Shmayda WT, Turnbull D, Williams CA, Campbell EM, Christopherson AR, Tabak M, Alexander NB, Farrell MP, Shuldberg C
Enhancements in Laser-Direct-Drive Nuclear Performance with Target Radius. Phys Rev Lett. 2026 Jan 30; 136(4):045101.
Enhancements in Laser-Direct-Drive Nuclear Performance with Target Radius.
Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M
IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. Vet Comp Oncol. 2017 Dec; 15(4):1240-1256.
IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017 04; 31(4):788-797.
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
Thomas CA, Rosenberg MJ, Theobald W, Knauer JP, Stoeckl C, Regan SP, Collins TJB, Goncharov VN, Betti R, Froula D, Deeney C, Anderson KS, Bauer KA, Bonino MJ, Cao D, Craxton RS, Edgell DH, Epstein R, Fess S, Forrest CJ, Glebov VY, Gopalaswamy V, Harding DR, Igumenshchev IV, Ivancic ST, Jacobs-Perkins DW, Janezic RT, Joshi T, Koch M, Kwiatkowski J, Lees A, Marshall FJ, Michalko M, Morse SFB, Patel D, Peebles JL, Radha PB, Rinderknecht HG, Sampat S, Sangster TC, Shah RC, Shmayda WT, Turnbull D, Williams CA, Campbell EM, Christopherson AR, Tabak M, Alexander NB, Farrell MP, Shuldberg C
Applications of a Rayleigh-Taylor model to direct-drive laser fusion. Phys Rev E. 2024 Oct; 110(4-2):045203.
Applications of a Rayleigh-Taylor model to direct-drive laser fusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Venous thromboembolism in malignancy. J Clin Oncol. 2000 Sep; 18(17):3065-7.
How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. J Clin Oncol. 2014 Nov 10; 32(32):3596-9.
How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis.
Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015 Jan 06; 162(1):27-34.
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014 Nov-Dec; 35(6):444-53.
The thrombogenicity of C1 esterase inhibitor (human): review of the evidence.
Current challenges in the management of hemophilia. Am J Manag Care. 2015 Mar; 21(6 Suppl):S112-22.
Current challenges in the management of hemophilia.
Targeted Anti-Anticoagulants. N Engl J Med. 2015 Aug 06; 373(6):569-71.
Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, Lim W, Douketis JD
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016 Jan; 41(1):154-64.
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.
McLintock C, Pabinger I, Bauer KA, Laffan M, Angchaisuksiri P, Rezende SM, Middeldorp S, Ross M
International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. J Thromb Haemost. 2016 Jan; 14(1):3-27.
International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis.
Parchem NL, Bauer KA, Cook CH, Mangino JE, Jones CD, Porter K, Murphy CV
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. Eur J Clin Microbiol Infect Dis. 2016 Sep; 35(9):1433-9.
Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.
Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency. Ann Pharmacother. 2016 09; 50(9):758-67.
Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency.
Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Liaw PC, Weitz JI, Julian JA
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thromb Res. 2016 Oct; 146:119-125.
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.
Stolla M, Chang S, Schulman S, Bauer K, Haspel R, Lerner AB
Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery. Br J Haematol. 2018 04; 181(1):143-145.
Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery.
Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA
The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol. 1997 Nov; 17(11):2825-9.
The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies.
Eriksson BI, Bauer KA, Lassen MR, Turpie AG
Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J Thromb Haemost. 2003 Feb; 1(2):383-4.
Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery.
Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest. 2004 Aug; 126(2):501-8.
Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
Wulf GM, Van Deerlin VM, Leonard DG, Bauer KA
Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene. Blood Coagul Fibrinolysis. 1999 Mar; 10(2):107-10.
Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene.
Hunault M, Arbini AA, Carew JA, Bauer KA
Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation. Br J Haematol. 1999 Jun; 105(4):1101-8.
Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation.
Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD
Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. Blood. 1992 Apr 15; 79(8):2034-8.
Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels.
Lassen MR, Bauer KA, Eriksson BI, Turpie AG
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002 May 18; 359(9319):1715-20.
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002; 20(1):37-52.
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
Bauer KA, Eriksson BI, Lassen MR, Turpie AG
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Curr Opin Pulm Med. 2002 Sep; 8(5):398-404.
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Miller GJ, Bauer KA, Cooper JA, Rosenberg RD
Activation of the coagulant pathway in cigarette smokers. Thromb Haemost. 1998 Mar; 79(3):549-53.
Activation of the coagulant pathway in cigarette smokers.
Hunault M, Arbini AA, Carew JA, Peyvandi F, Bauer KA
Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood. 1999 Feb 15; 93(4):1237-44.
Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII.
Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun; 4(6):1208-14.
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001 Nov 01; 345(18):1305-10.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Miller GJ, Bauer KA, Howarth DJ, Mitchell JP, Cooper JA
Does inflammatory proteolytic activity contribute to the increased factor IX activation peptide in men at high risk of coronary heart disease? A preliminary study. Thromb Haemost. 2002 Mar; 87(3):415-20.
Does inflammatory proteolytic activity contribute to the increased factor IX activation peptide in men at high risk of coronary heart disease? A preliminary study.
Cella G, Randi ML, Sbarai A, Bauer KA, Barzega S, Rosenberg RD
Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders. Haematologica. 2002 Jun; 87(6):671-2.
Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders.
Activation of the factor VII-tissue factor pathway. Thromb Haemost. 1997 Jul; 78(1):108-11.
Activation of the factor VII-tissue factor pathway.
Bailliere's best practice & research. Clinical haematology
Activation markers of coagulation. Baillieres Best Pract Res Clin Haematol. 1999 Sep; 12(3):387-406.
Peyvandi F, Carew JA, Perry DJ, Hunault M, Khanduri U, Perkins SJ, Mannucci PM, Bauer KA
Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood. 2001 Feb 15; 97(4):960-5.
Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene.
Hormone replacement therapy and the factor V Leiden mutation. Arterioscler Thromb Vasc Biol. 2002 Jun 01; 22(6):879-80.
Hormone replacement therapy and the factor V Leiden mutation.
Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10; 348(15):1425-34.
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. Thromb Res. 1991 Sep 15; 63(6):617-28.
Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements.
Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Piñango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 Oct 12; 294(14):1799-809.
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP
Venous thrombosis in the elderly: more questions than answers. Blood. 2007 Nov 01; 110(9):3097-101.
Venous thrombosis in the elderly: more questions than answers.
Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD
Haemostatic changes that constitute the hypercoagulable state. Lancet. 1991 Oct 26; 338(8774):1079.
Haemostatic changes that constitute the hypercoagulable state.
Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM
Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 2001 Nov 01; 98(9):2726-9.
Thrombogenic potential of human coronary atherosclerotic plaques.
The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 2001 Sep 04; 135(5):367-73.
The thrombophilias: well-defined risk factors with uncertain therapeutic implications.
Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL
The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost. 2000 Mar; 83(3):366-70.
The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred.
Bauer KA, Eichinger S, Mannucci PM, Rosenberg RD
Determinants of coagulation activation in humans. Haemostasis. 1996; 26 Suppl 1:72-5.
Determinants of coagulation activation in humans.
Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007 Sep; 5(9):1854-61.
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison.
Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, ten Cate H
The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost. 2007 Sep; 5(9):1896-903.
The plasma kallikrein-kinin system and risk of cardiovascular disease in men.
Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000 Dec 05; 102(23):2816-22.
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease.
Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, Bertocchi F, Rosenberg RD, Mannucci PM
Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003 Oct 15; 102(8):2731-5.
Coagulation activation and long-term outcome in acute coronary syndromes.
The American journal of clinical nutrition
Does a prethrombotic state exist? If so, what is it? Am J Clin Nutr. 1992 10; 56(4 Suppl):787S-788S.
Does a prethrombotic state exist? If so, what is it?
Carew JA, Pollak ES, Lopaciuk S, Bauer KA
A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency. Blood. 2000 Dec 15; 96(13):4370-2.
A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency.
Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 1992 Apr 15; 79(8):2039-47.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Press RD, Bauer KA, Kujovich JL, Heit JA
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002 Nov; 126(11):1304-18.
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders.
Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U
Inherited thrombophilia: Part 1. Thromb Haemost. 1996 Nov; 76(5):651-62.
Freedman RA, Bauer KA, Neuberg DS, Zwicker JI
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. Blood Coagul Fibrinolysis. 2008 Jan; 19(1):55-9.
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage.
Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G
Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 01; 56(3):425-30.
Tissue factor gene expression in acute myeloblastic leukemia.
Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 01; 58 Suppl 2:S14-7.
Fondaparinux sodium: a selective inhibitor of factor Xa.
Carew JA, Basso F, Miller GJ, Hawe E, Jackson AA, Humphries SE, Bauer KA
A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost. 2003 Oct; 1(10):2179-85.
A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease.
Hypercoagulability: too many tests, too much conflicting data. Hematology Am Soc Hematol Educ Program. 2002; 353-68.
Hypercoagulability: too many tests, too much conflicting data.
ARP1 interacts with the 5' flanking region of the coagulation factor VII gene. J Thromb Haemost. 2003 Jun; 1(6):1220-7.
ARP1 interacts with the 5' flanking region of the coagulation factor VII gene.
Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol. 1991 Dec; 79(4):606-11.
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. Blood. 1998 Sep 01; 92(5):1639-45.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter.
New anticoagulants. Curr Opin Hematol. 2008 Sep; 15(5):509-15.
Ganetsky M, Lopez G, Coreanu T, Novack V, Horng S, Shapiro NI, Bauer KA
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
Risk of Intracranial Hemorrhage in Ground-level Fall With Antiplatelet or Anticoagulant Agents. Acad Emerg Med. 2017 10; 24(10):1258-1266.
Risk of Intracranial Hemorrhage in Ground-level Fall With Antiplatelet or Anticoagulant Agents.
Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH
The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion. 2004 Nov; 44(11):1562-6.
The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004 Dec; 2(12):2133-7.
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001 Nov 01; 345(18):1298-304.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Ireland HA, Cooper JA, Drenos F, Acharya J, Mitchell JP, Bauer KA, Morrissey JH, Esnouf MP, Humphries SE
FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1968-74.
FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men.
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002 May 18; 359(9319):1721-6.
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Peyvandi F, De Cristofaro R, Akhavan S, Carew JA, Landolfi R, Bauer KA, Mannucci PM
Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thromb Haemost. 2002 Nov; 88(5):750-5.
Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity.
Journal of the Southern Orthopaedic Association
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc. 2002; 11(4):182-8.
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. J South Orthop Assoc. 2002; 11(4):197-202.
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.
A simple, automated functional assay for protein C. Am J Clin Pathol. 1989 Aug; 92(2):210-3.
A simple, automated functional assay for protein C.
Polymyositis complicating pregnancy. Arch Intern Med. 1979 Apr; 139(4):449.
Role of thrombophilia in deciding on the duration of anticoagulation. Semin Thromb Hemost. 2004 Dec; 30(6):633-7.
Role of thrombophilia in deciding on the duration of anticoagulation.
The challenge of hospital-related thrombosis. Blood. 2017 07 13; 130(2):97-98.
The challenge of hospital-related thrombosis.
James AH, Bates SM, Bauer KA, Branch W, Mann K, Paidas M, Silverman N, Konkle BA
Management of hereditary antithrombin deficiency in pregnancy. Thromb Res. 2017 Sep; 157:41-45.
Management of hereditary antithrombin deficiency in pregnancy.
Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. Am J Med. 1983 Jan; 74(1):33-9.
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor.
The role of other hemostatic factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2006 Mar; 26(3):e29.
The role of other hemostatic factors in predicting arterial thrombotic events.
Lindon JN, Salzman EW, Merrill EW, Dincer AK, Labarre D, Bauer KA, Rosenberg RR
Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces. J Lab Clin Med. 1985 Feb; 105(2):219-26.
Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces.
Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD
Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990 Aug 15; 76(4):731-6.
Factor IX is activated in vivo by the tissue factor mechanism.
Haspel J, Bauer K, Goehler A, Roberts DH
Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis. Chest. 2009 May; 135(5):1243-1251.
Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis.
Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, Karcher RB, Berry CA, Keaton KL, Stowell SA
The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol. 2010 Mar; 9(1):41-8.
The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education.
Shapiro ME, Rodvien R, Bauer KA, Salzman EW
Acute aortic thrombosis in antithrombin III deficiency. JAMA. 1981 May 01; 245(17):1759-61.
Acute aortic thrombosis in antithrombin III deficiency.
Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994 Jul; 90(1):61-8.
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.
Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood. 2006 Aug 15; 108(4):1280-3.
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.
Hematology/oncology clinics of North America
Thrombophilias in pregnancy. Hematol Oncol Clin North Am. 2011 Apr; 25(2):323-33, viii.
Carroll BJ, Pemberton H, Bauer KA, Chu LM, Weinstein JL, Levarge BL, Pinto DS
Initiation of a Multidisciplinary, Rapid Response Team to Massive and Submassive Pulmonary Embolism. Am J Cardiol. 2017 Oct 15; 120(8):1393-1398.
Initiation of a Multidisciplinary, Rapid Response Team to Massive and Submassive Pulmonary Embolism.
Clinical advances in hematology & oncology : H&O
Thrombophilia evaluation: the value of testing relatives. Clin Adv Hematol Oncol. 2010 Apr; 8(4):229-31.
Thrombophilia evaluation: the value of testing relatives.
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 1987 Aug; 70(2):343-50.
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.
Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD
Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost. 1994 Jun; 71(6):737-40.
Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost. 1995 Nov; 74(5):1255-8.
Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis.
New markers for in vivo coagulation. Curr Opin Hematol. 1994 Sep; 1(5):341-6.
Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003 Mar; 43(3):390-4.
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI
Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012 Aug 07; 345:e4944.
Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.
van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood. 1990 Dec 01; 76(11):2284-9.
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005 Oct; 25(10):2043-53.
Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Management of thrombophilia. J Thromb Haemost. 2003 Jul; 1(7):1429-34.
Pantanowitz L, Bauer K, Tefs K, Schuster V, Balogh K, Pilch BZ, Adcock D, Cirovic C, Kocher O
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. Int J Gynecol Pathol. 2004 Jul; 23(3):292-5.
Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency.
Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007 Jun; 97(6):931-7.
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
ACP Journal Club. Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patients. Ann Intern Med. 2012 Apr 17; 156(8):JC4-06.
ACP Journal Club. Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patients.
Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost. 2003 Aug; 90(2):364-6.
Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration.
Inherited thrombophilia: Part 2. Thromb Haemost. 1996 Dec; 76(6):824-34.
Arbini AA, Pollak ES, Bayleran JK, High KA, Bauer KA
Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. Blood. 1997 Jan 01; 89(1):176-82.
Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter.
Ballen KK, Canoso R, Seiler M, Neish A, Bauer KA
Neuroendocrine carcinoma in a patient with hairy cell leukemia: a case report. Med Pediatr Oncol. 1992; 20(4):349-51.
Neuroendocrine carcinoma in a patient with hairy cell leukemia: a case report.
The Journal of the American Academy of Orthopaedic Surgeons
Fondaparinux. J Am Acad Orthop Surg. 2004 Nov-Dec; 12(6):371-5.
Merlini PA, Ardissino D, Rosenberg RD, Colombi E, Agricola P, Oltrona L, Ottani F, Galvani M, Bauer KA, Bottasso B, Bertocchi F, Mannucci PM
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2000 Sep; 20(9):2162-6.
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost. 2000; 26(4):401-5.
Recombinant factor VIIa for the treatment of congenital factor VII deficiency.
van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990 Jun 07; 322(23):1622-7.
Activation of coagulation after administration of tumor necrosis factor to normal subjects.
Italian heart journal : official journal of the Italian Federation of Cardiology
Hemostatic markers and prognosis in ischemic heart disease. Ital Heart J. 2001 Jul; 2(7):499-501.
Hemostatic markers and prognosis in ischemic heart disease.
Moons AH, Peters RJ, Cate Ht, Bauer KA, Vlasuk GP, Büller HR, Levi M
Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost. 2002 Oct; 88(4):627-31.
Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.
Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost. 2010 Feb; 8(2):263-8.
Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review.
Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009 Jan; 101(1):68-76.
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. Am J Med. 1989 Sep 11; 87(3B):39S-43S.
Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation.
Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989 Jul; 74(1):165-72.
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans.
Sala N, Borrell M, Bauer KA, Viganò-D'Angelo S, Fontcuberta J, Félez J, Rutllant ML
Dysfunctional activated protein C (PC Cádiz) in a patient with thrombotic disease. Thromb Haemost. 1987 Apr 07; 57(2):183-6.
Dysfunctional activated protein C (PC Cádiz) in a patient with thrombotic disease.
Prochownik EV, Antonarakis S, Bauer KA, Rosenberg RD, Fearon ER, Orkin SH
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med. 1983 Jun 30; 308(26):1549-52.
Molecular heterogeneity of inherited antithrombin III deficiency.
Activation markers of coagulation. Baillieres Clin Haematol. 1994 Sep; 7(3):523-40.
Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost. 1995 Jul; 74(1):94-100.
Management of patients with hereditary defects predisposing to thrombosis including pregnant women.
Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47(3):203-16.
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Bauer KA, Kass BL, Beeler DL, Rosenberg RD
Detection of protein C activation in humans. J Clin Invest. 1984 Dec; 74(6):2033-41.
Detection of protein C activation in humans.
Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD
The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995 Jan; 73(1):82-6.
The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men.
Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD
Detection of factor X activation in humans. Blood. 1989 Nov 01; 74(6):2007-15.
Detection of factor X activation in humans.
Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest. 1987 Dec; 80(6):1527-34.
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.
Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis. 1996; 26 Suppl 1:155-8.
Treatment of factor VII deficiency with recombinant factor VIIa.
Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol. 1996 Nov; 16(11):1333-9.
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.
Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD
Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992 Oct 05; 68(4):392-5.
Coagulation activation following estrogen administration to postmenopausal women.
Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004 Dec; 2(12):2107-14.
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway.
Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg RD, Miller GJ
Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost. 2000 Sep; 84(3):396-400.
Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations.
Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ
A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood. 1992 Jan 15; 79(2):389-97.
A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage.